Maraviroc - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for maraviroc and what is the scope of patent protection?
Maraviroc
is the generic ingredient in two branded drugs marketed by Viiv Hlthcare and Hetero Labs Ltd Iii, and is included in three NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Maraviroc has ninety-six patent family members in fifty-five countries.
There are two drug master file entries for maraviroc. Two suppliers are listed for this compound.
Summary for maraviroc
International Patents: | 96 |
US Patents: | 2 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 3 |
Drug Master File Entries: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 139 |
Patent Applications: | 6,786 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in maraviroc? | maraviroc excipients list |
DailyMed Link: | maraviroc at DailyMed |
Recent Clinical Trials for maraviroc
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Orlando Immunology Center | Phase 4 |
Centro de Investigación en. Enfermedades Infecciosas, Mexico | Phase 2 |
Hospital General de México Dr. Eduardo Liceaga | Phase 2 |
Pharmacology for maraviroc
Drug Class | CCR5 Co-receptor Antagonist |
Mechanism of Action | Chemokine Co-receptor 5 Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for maraviroc
US Patents and Regulatory Information for maraviroc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-002 | Aug 6, 2007 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Hetero Labs Ltd Iii | MARAVIROC | maraviroc | TABLET;ORAL | 203347-001 | Feb 7, 2022 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for maraviroc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-004 | Nov 4, 2016 | See Plans and Pricing | See Plans and Pricing |
Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | See Plans and Pricing | See Plans and Pricing |
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-003 | Nov 4, 2016 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for maraviroc
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2408909 | DERIVES DU TROPANE UTILES EN THERAPIE (AZABICYCLO[3.2.1]OCTANE TRIAZOLYL TROPANE DERIVATIVES AS CCRS5 MODULATORS) | See Plans and Pricing |
Austria | 407134 | See Plans and Pricing | |
Malaysia | 153023 | TROPANE DERIVATIVES USEFUL IN THERAPY | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for maraviroc
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1284974 | PA 2008 004, C 1284974 | Lithuania | See Plans and Pricing | PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918 |
1284974 | PA2008004,C1284974 | Lithuania | See Plans and Pricing | PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 0070918 |
1284974 | 122008000011 | Germany | See Plans and Pricing | PRODUCT NAME: 4,4-DIFLUORO-N-((1S)-3-((1R,3S,5S)-3-(3-METHYL-5-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO(3.2.1)OCTAN-8-YL)-1-PHENYLPROPYL)CYCLOHEXANECARBOXAMIDE; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.